KHPG(SZ:002773) Zhi Tong Cai Jing·2025-12-08 00:13Core Viewpoint - Kanghong Pharmaceutical's eye injection, Kangbaxip, has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, reflecting recognition of its innovation and clinical value by the National Healthcare Security Administration [1] Group 1: Product Inclusion - Kangbaxip is the only domestic innovative drug covering four major indications for retinal diseases in the current catalog [1] - The inclusion in the regular catalog management will enhance the stability and accessibility of medication for patients [1] Group 2: Ongoing Clinical Trials - The company is actively conducting Phase III clinical trials for high-dose Kangbaxip [1] - Clinical trials for gene therapy drugs KH631 and KH658 are being carried out in both China and the United States [1] - The aim is to benefit more patients through high-quality innovation [1]